
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc has demonstrated a solid financial performance characterized by an expansion in gross margin by 110 basis points year-over-year to 70%, due to higher average selling prices, manufacturing efficiencies, and an advantageous product mix. The company reported a 15% increase in revenue and a 12% increase in operating income to $16.1 million, translating to an operating margin of 25%, indicating robust operational efficiency and profitability. Additionally, positive momentum is projected for the year, with expectations of a gross margin of 69.7% and an operating income forecasted to reach $60.9 million, reflecting a significant 17% year-over-year increase, further bolstering the positive outlook.
Bears say
LeMaitre Vascular is anticipating a slight decline in its full-year operating margin to 24%, reflecting the impact of seasonality in its business operations. Additionally, the company's target for sales representatives has been reduced from 170 to 165, indicating possible concerns about sales growth and market penetration. Furthermore, the reduction in research and development spending to 6% of revenue raises concerns about the firm's commitment to innovation, which, combined with potential competitive pressures and regulatory challenges, contributes to a negative outlook on the company's future performance.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares